{"id":78747,"date":"2026-09-04T15:47:35","date_gmt":"2026-09-04T07:47:35","guid":{"rendered":"https:\/\/flcube.com\/?p=78747"},"modified":"2026-09-04T15:47:36","modified_gmt":"2026-09-04T07:47:36","slug":"fosun-pharmas-luvometinib-wins-nmpa-approval-for-nf1-associated-plexiform-neurofibromas-in-adults","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78747","title":{"rendered":"Fosun Pharma\u2019s luvometinib Wins NMPA Approval for NF1-Associated Plexiform Neurofibromas in Adults"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2196:HKG\">HKG: 2196<\/a>)<\/strong> announced that its drug <strong>luvometinib<\/strong> has received approval from <strong>China\u2019s National Medical Products Administration (NMPA)<\/strong> for a new indication: the treatment of <strong>adult patients with neurofibromatosis type 1 (NF1)<\/strong> who have <strong>symptomatic, inoperable plexiform neurofibromas (PN)<\/strong>. The approval extends the selective <strong>MEK1\/2 inhibitor\u2019s<\/strong> footprint across rare diseases, adding an adult population to its existing pediatric and histiocytic indications.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agency<\/td><td><strong>National Medical Products Administration (NMPA)<\/strong>, China<\/td><\/tr><tr><td>Approval Type<\/td><td>New indication approval<\/td><\/tr><tr><td>Product<\/td><td><strong>luvometinib<\/strong><\/td><\/tr><tr><td>Indication<\/td><td>Adult patients with <strong>neurofibromatosis type 1 (NF1)<\/strong> with <strong>symptomatic, inoperable plexiform neurofibromas (PN)<\/strong><\/td><\/tr><tr><td>Date<\/td><td>03 Sept 2026<\/td><\/tr><tr><td>Next Steps<\/td><td>Commercialization of the new indication in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>luvometinib<\/strong>, a selective <strong>MEK1\/2 inhibitor<\/strong> developed by <strong>Fosun Pharma<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Inhibition of MEK1\/2 signaling within the RAS\u2013RAF\u2013MEK\u2013ERK pathway, a key driver in NF1-related tumor growth<\/li>\n\n\n\n<li><strong>Approved Indications (cumulative):<\/strong>\n<ul class=\"wp-block-list\">\n<li>Adult patients with <strong>Langerhans cell histiocytosis (LCH)<\/strong> and <strong>histiocytic neoplasms<\/strong><\/li>\n\n\n\n<li>Pediatric and adolescent patients aged <strong>2 years and older<\/strong> with <strong>symptomatic, inoperable plexiform neurofibromas (PN)<\/strong> associated with <strong>NF1<\/strong><\/li>\n\n\n\n<li>Pediatric and adolescent patients aged <strong>2 years and older<\/strong> with <strong>relapsed or refractory LCH<\/strong> following systemic therapy<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>New Addition:<\/strong> Adult NF1-PN indication, completing coverage of this rare disease across both pediatric and adult age groups<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-status-amp-clinical-outlook\" class=\"wp-block-heading\">Development Status &amp; Clinical Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The adult approval complements the existing pediatric NF1-PN indication, enabling <strong>luvometinib<\/strong> to address the full age spectrum of patients with symptomatic, inoperable PN<\/li>\n\n\n\n<li>Plexiform neurofibromas are a major cause of morbidity in NF1, and inoperable cases have historically lacked approved targeted options in adults<\/li>\n\n\n\n<li>The drug\u2019s multi-indication label across NF1 and histiocytic disorders strengthens its positioning in rare disease and oncology<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rare disease positioning:<\/strong> Adult NF1-PN is an underserved segment with limited approved therapies, giving <strong>luvometinib<\/strong> a differentiated foothold in China<\/li>\n\n\n\n<li><strong>Label expansion value:<\/strong> Each new indication broadens the addressable patient population and reinforces <strong>Fosun Pharma\u2019s<\/strong> rare disease portfolio<\/li>\n\n\n\n<li><strong>Competitive landscape:<\/strong> As a selective MEK1\/2 inhibitor with multiple approved indications, <strong>luvometinib<\/strong> gains clinical credibility against other targeted agents in the class<\/li>\n\n\n\n<li><strong>Portfolio momentum:<\/strong> The approval underscores <strong>Fosun Pharma\u2019s<\/strong> (SHA: 600196, HKG: 2196) strategy of expanding innovative assets across oncology and rare diseases<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements:<\/strong> This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding drug commercialization, market potential and indication expansion are forward-looking and subject to risks and uncertainties, including competitive developments, reimbursement outcomes and clinical adoption. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/600196_20260904_BVG8.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600196_20260904_BVG8.\"><\/object><a id=\"wp-block-file--media-ab5e3bd4-7b4e-4d6e-b0ce-2939f14c8499\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/600196_20260904_BVG8.pdf\">600196_20260904_BVG8<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/600196_20260904_BVG8.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ab5e3bd4-7b4e-4d6e-b0ce-2939f14c8499\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its drug luvometinib&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,159,893,15,892,33],"class_list":["post-78747","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-fosun-pharmaceutical","tag-hkg-2196","tag-product-approvals","tag-sha-600196","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma\u2019s luvometinib Wins NMPA Approval for NF1-Associated Plexiform Neurofibromas in Adults - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its drug luvometinib has received approval from China\u2019s National Medical Products Administration (NMPA) for a new indication: the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The approval extends the selective MEK1\/2 inhibitor\u2019s footprint across rare diseases, adding an adult population to its existing pediatric and histiocytic indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78747\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma\u2019s luvometinib Wins NMPA Approval for NF1-Associated Plexiform Neurofibromas in Adults\" \/>\n<meta property=\"og:description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its drug luvometinib has received approval from China\u2019s National Medical Products Administration (NMPA) for a new indication: the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The approval extends the selective MEK1\/2 inhibitor\u2019s footprint across rare diseases, adding an adult population to its existing pediatric and histiocytic indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78747\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-04T07:47:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-04T07:47:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78747#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78747\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma\u2019s luvometinib Wins NMPA Approval for NF1-Associated Plexiform Neurofibromas in Adults\",\"datePublished\":\"2026-09-04T07:47:35+00:00\",\"dateModified\":\"2026-09-04T07:47:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78747\"},\"wordCount\":450,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"Product approvals\",\"SHA: 600196\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78747#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78747\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78747\",\"name\":\"Fosun Pharma\u2019s luvometinib Wins NMPA Approval for NF1-Associated Plexiform Neurofibromas in Adults - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-04T07:47:35+00:00\",\"dateModified\":\"2026-09-04T07:47:36+00:00\",\"description\":\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its drug luvometinib has received approval from China\u2019s National Medical Products Administration (NMPA) for a new indication: the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The approval extends the selective MEK1\\\/2 inhibitor\u2019s footprint across rare diseases, adding an adult population to its existing pediatric and histiocytic indications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78747#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78747\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78747#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma\u2019s luvometinib Wins NMPA Approval for NF1-Associated Plexiform Neurofibromas in Adults\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma\u2019s luvometinib Wins NMPA Approval for NF1-Associated Plexiform Neurofibromas in Adults - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its drug luvometinib has received approval from China\u2019s National Medical Products Administration (NMPA) for a new indication: the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The approval extends the selective MEK1\/2 inhibitor\u2019s footprint across rare diseases, adding an adult population to its existing pediatric and histiocytic indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78747","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma\u2019s luvometinib Wins NMPA Approval for NF1-Associated Plexiform Neurofibromas in Adults","og_description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its drug luvometinib has received approval from China\u2019s National Medical Products Administration (NMPA) for a new indication: the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The approval extends the selective MEK1\/2 inhibitor\u2019s footprint across rare diseases, adding an adult population to its existing pediatric and histiocytic indications.","og_url":"https:\/\/flcube.com\/?p=78747","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-04T07:47:35+00:00","article_modified_time":"2026-09-04T07:47:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78747#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78747"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma\u2019s luvometinib Wins NMPA Approval for NF1-Associated Plexiform Neurofibromas in Adults","datePublished":"2026-09-04T07:47:35+00:00","dateModified":"2026-09-04T07:47:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78747"},"wordCount":450,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Fosun Pharmaceutical","HKG: 2196","Product approvals","SHA: 600196","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78747#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78747","url":"https:\/\/flcube.com\/?p=78747","name":"Fosun Pharma\u2019s luvometinib Wins NMPA Approval for NF1-Associated Plexiform Neurofibromas in Adults - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-04T07:47:35+00:00","dateModified":"2026-09-04T07:47:36+00:00","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its drug luvometinib has received approval from China\u2019s National Medical Products Administration (NMPA) for a new indication: the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The approval extends the selective MEK1\/2 inhibitor\u2019s footprint across rare diseases, adding an adult population to its existing pediatric and histiocytic indications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78747#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78747"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78747#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma\u2019s luvometinib Wins NMPA Approval for NF1-Associated Plexiform Neurofibromas in Adults"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78747"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78747\/revisions"}],"predecessor-version":[{"id":78749,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78747\/revisions\/78749"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}